[FCHL.OB] FAIRCHILD INTL CO › 0.78
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
development and marketing of alternate fuels
[ARDM] ARADIGM CP › 0.93
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Aradigm Corporation engages in the development and commercialization of noninvasive drug delivery systems. It develops needle-free drug delivery systems that enable patients to self-administer liquid drugs that would otherwise be given by injection. The company offers hand-held AERx technology for the rapid and reproducible delivery of a range of pharmaceutical drugs and biotech compounds through the lung, as well as pen-sized, needle-free Intraject system to deliver drugs to the subcutaneous layer of the skin. Aradigm also provides AERx insulin Diabetes Management System, which permits patients with diabetes to noninvasively self-administer insulin. Its other early-stage AERx programs include liposomal ciprofloxacin under agreement with Canada’s Department of Defence; Hydroxycholoroquine for the treatment of asthma and an undisclosed drug that targets a common respiratory disease; Intraject, a pen-sized, prefilled, single-use system to enable patients and healthcare workers to deliver measured doses of drug to the subcutaneous layer of the skin without the use of needles; Intraject Sumatriptan for the delivery of sumatriptan; and other Intraject applications.
[AKN] AKORN INC › 4.39
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Akorn, Inc. engages in the development, manufacture, and marketing of diagnostic and therapeutic pharmaceuticals in areas, such as ophthalmology, rheumatology, anesthesia, and antidotes, primarily in the United States. The company operates in three segments: Ophthalmic, Injectable, and Contract Services. Ophthalmic segment markets a line of diagnostic and therapeutic pharmaceutical products. Diagnostic products include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes. Therapeutic products include antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications. Its nonpharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments, lid cleansers, vitamin supplements, and contact lens accessories. It offers its products through outside sales representatives, who sell directly to physicians and group practices; in-house sales (telemarketing) and customer service (catalog sales) to optometrists and other customers; and a national accounts group that sells to wholesalers, retail chains, and other groups. Injectable segment markets a line of injectable pharmaceutical products, including antidotes, anesthesia, and products used in the treatment of rheumatoid arthritis and pain management. It markets its products to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The Contract Services segment manufactures products for third party pharmaceutical and biotechnology customers based on their specifications.
[HBX] HANA BIOSCIENCES › 5.58
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Hana Biosciences, Inc. operates as a biopharmaceutical company that acquires, develops, and commercializes products to advance cancer care. It develops products that include Talotrexin (PT-523), a novel nonpolyglutamatable antifolate drug that has demonstrated enhanced antitumor activity in cancers by targeting DHFR to prevent DNA synthesis and inhibit tumor growth; IPdR, a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor; and Zensana (ondansetron oral spray), a novel oral spray formulation of ondansetron that uses highly-absorptive surfaces of the oral mucosa to deliver drug directly into the blood stream to prevent chemotherapy, radiation, and post-operative induced nausea and vomiting. Talotrexin is in phase I clinical trials in patients with solid tumors, and in phase I/II study in non-small cell lung cancer and acute lymphocytic leukemia. IPdR is in Phase I clinical trials and Zensana is being developed as a 505(b)(2) registration.
[NRVN] NATURE VISION INC › 6.34
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Nature Vision, Inc. engages in design, manufacture, and marketing of video viewing systems for the sport fishing and hunting market, as well as various photographic products and accessories primarily in the United States. The company operates in two divisions, Nature Vision and Photo Control. Nature Vision division produces and markets video viewing systems for the sport fishing market, and other video-based consumer and industrial products. This division offers underwater viewing systems, hunting products comprising camera systems and hearing enhancers, ice fishing products consisting of Buzz Stix ice fishing rod product line, as well as industrial products, including viewing systems for water well, automotive, and building inspections. The Photo Control division manufactures and markets various photographic products, including professional Camerz film cameras; photographic accessories; Norman electronic flash equipment; and the Lindahl product line consisting of lens shades, light filters, and flash brackets. This division also offers peripheral products for the videoconferencing and the audiovisual markets.
[ABHH.OB] AMERICAN BK NT HO › 6.40
American Bank Note Holographics, Inc. engages in originating, mass producing, and marketing holograms. The company’s holograms are used primarily for security applications, such as counterfeiting protection for credit and other transaction cards, and identification cards and documents of value, as well as for tamper resistance, and authentication of consumer and industrial products. It also produces nonsecure holograms for packaging and promotional applications. The company sells its products primarily to credit card issuers, government agencies, and corporations with counterfeiting or other security problems worldwide.
[ELOY] ELOYALTY CORP › 7.67
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
eLoyalty Corporation provides customer relationship management (CRM) related professional services in North America and Europe. It provides management consulting, systems integration, and managed services. The company’s enterprise CRM services and solutions include creating customer strategies; defining technical architectures; selecting, implementing, and integrating CRM and analytics software applications; providing ongoing support for multivendor systems; and hosting application environments. eLoyalty’s consulting services include evaluating, selecting, building, or integrating CRM systems for clients. The company’s managed services involve a range of contact center services from routine maintenance and technology upgrades to the resolution of issues that involve multiple technology components and vendors. Its managed services also include hosted customer data management and campaign management services. eLoyalty also resells third-party software and hardware.
update: [SELA.OB] SEITEL INC › 1.62
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G |
